Advances in Neurofibromatosis 2 (NF2): A Workshop Report

DAVID J. LIM*, ALLAN E. RUBENSTEIN, D. GARETH EVANS, TYLER JACKS, BERND G. SEIZINGER, MICHAEL E. BASER, DAVID BEEBE, DERALD E. BRACKMANN, E. ANTONIO CHIOCCA, RICHARD G. FEHON, MARC0 GIOVANNINI, ROBERT GLAZER, JAMES F. GUSELLA, DAVID H. GUTMANN, BRUCE KORF, FRANK LIEBERMAN, ROBERT MARTUZA, ANDREA I. McCLATCHEY, DILYS M. PARRY, STEFAN M. PULST, VIJAYA RAMESH, W. JAY RAMSEY, NANCY RATNER, J. LYNN RUTKOWSKI, MARTIN RUTTLEDGE and DAVID E. WEINSTEIN

[1]  M. Seashore.  Gene therapy for neurological disorders and brain tumors , 2000 .

[2]  A. Berns,et al.  Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. , 1999, Genes & development.

[3]  L. Kluwe,et al.  Germ-line NF2 mutations and disease severity in neurofibromatosis type 2 patients with retinal abnormalities. , 1999, American journal of human genetics.

[4]  U. Thorgeirsson,et al.  Tumor angiogenesis: biology and therapeutic prospects. , 1998, In vivo.

[5]  N. Ratner,et al.  Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells , 1998, Oncogene.

[6]  E. Constant.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2 , 1998 .

[7]  T Salditt,et al.  An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. , 1998, Science.

[8]  R. Fehon,et al.  Structural Analysis of Drosophila Merlin Reveals Functional Domains Important for Growth Control and Subcellular Localization , 1998, The Journal of cell biology.

[9]  D. Evans,et al.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. , 1998, Journal of medical genetics.

[10]  J. Marshall,et al.  Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  R. Chung,et al.  An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy , 1998, Nature Biotechnology.

[12]  T. Jacks,et al.  Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. , 1998, Genes & development.

[13]  D. Russell,et al.  Human gene targeting by viral vectors , 1998, Nature Genetics.

[14]  S. Pulst,et al.  Neurofibromatosis 2 tumour suppressor schwannomin interacts with βII-spectrin , 1998, Nature Genetics.

[15]  D. Gutmann,et al.  Defects in neurofibromatosis 2 protein function can arise at multiple levels. , 1998, Human molecular genetics.

[16]  J. Behr,et al.  Monomolecular collapse of plasmid DNA into stable virus-like particles. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Beaudet,et al.  Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity , 1998, Nature Genetics.

[18]  G. Thomas,et al.  Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane. , 1998, Human molecular genetics.

[19]  J. Gusella,et al.  NHE-RF, a Regulatory Cofactor for Na+-H+Exchange, Is a Common Interactor for Merlin and ERM (MERM) Proteins* , 1998, The Journal of Biological Chemistry.

[20]  L. Kluwe,et al.  Skin abnormalities in neurofibromatosis 2. , 1997, Archives of dermatology.

[21]  D. Lenartz,et al.  Clonality of multiple meningiomas. , 1997, Journal of neurosurgery.

[22]  J. Gusella,et al.  Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. , 1997, American journal of human genetics.

[23]  D. Gutmann,et al.  Interdomain binding mediates tumor growth suppression by the NF2 gene product , 1997, Oncogene.

[24]  A. Bretscher,et al.  Identification of EBP50: A PDZ-containing Phosphoprotein that Associates with Members of the Ezrin-Radixin-Moesin Family , 1997, The Journal of cell biology.

[25]  P. Black,et al.  Detection of activated platelet-derived growth factor receptors in human meningioma. , 1997, Cancer research.

[26]  A. Ullrich,et al.  Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  A. Stemmer-Rachamimov,et al.  Expression of NF2-encoded merlin and related ERM family proteins in the human central nervous system. , 1997, Journal of neuropathology and experimental neurology.

[28]  T. Jacks,et al.  The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. , 1997, Genes & development.

[29]  J. Whelan,et al.  Progress in transcriptionally targeted and regulatable vectors for genetic therapy. , 1997, Human gene therapy.

[30]  A. Berns,et al.  Cre-mediated somatic site-specific recombination in mice. , 1997, Nucleic acids research.

[31]  R. Fehon,et al.  Isolation of mutations in the Drosophila homologues of the human Neurofibromatosis 2 and yeast CDC42 genes using a simple and efficient reverse-genetic method. , 1997, Genetics.

[32]  D. Evans,et al.  Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[33]  R. Fahlbusch,et al.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. , 1997, Journal of neurosurgery.

[34]  S. Pulst,et al.  Immunohistochemical Detection of Schwannomin and Neurofibromin in Vestibular Schwannomas, Ependymomas and Meningiomas , 1997, Journal of neuropathology and experimental neurology.

[35]  S. Tsukita,et al.  ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. , 1997, Trends in biochemical sciences.

[36]  D. Gutmann,et al.  Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells , 1996, Journal of neuroscience research.

[37]  G. Lemke,et al.  Schwann cell differentiation. , 1996, Current opinion in cell biology.

[38]  W. Yung,et al.  Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  J. Vos,et al.  A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo , 1996, Journal of virology.

[40]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[41]  P. Wild,et al.  Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells , 1996, Journal of virology.

[42]  L. Kluwe,et al.  Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes , 1996, Human Genetics.

[43]  J. Gusella,et al.  The merlin tumor suppressor localizes preferentially in membrane ruffles. , 1996, Oncogene.

[44]  S. Pulst,et al.  Phenotypic variability in monozygotic twins with neurofibromatosis 2. , 1996, American journal of medical genetics.

[45]  M. Kaiser-Kupfer,et al.  Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. , 1996, American journal of human genetics.

[46]  J. Gusella,et al.  Frequency and distribution of NF2 mutations in schwannomas , 1996, Genes, chromosomes & cancer.

[47]  Shannon R. Magari,et al.  A humanized system for pharmacologic control of gene expression , 1996, Nature Medicine.

[48]  G. Rubin,et al.  The Role of the Genome Project in Determining Gene Function: Insights from Model Organisms , 1996, Cell.

[49]  J. Wilson,et al.  Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. , 1996, Human gene therapy.

[50]  R. Weksberg,et al.  Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. , 1996, American journal of human genetics.

[51]  S. Pulst,et al.  Neurofibromatosis 2 antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells. , 1996, Oncogene.

[52]  J. Bruce,et al.  Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas. , 1996, Neurosurgery.

[53]  B. Monia,et al.  Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-ras* , 1996, The Journal of Biological Chemistry.

[54]  E. Makariou,et al.  Growth Rate Characteristics of Acoustic Neuromas Associated With Neurofibromatosis Type 2 , 1996, The Laryngoscope.

[55]  R. Fehon,et al.  Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin , 1996, The Journal of cell biology.

[56]  S. Pulst,et al.  The neuroimaging and clinical spectrum of neurofibromatosis 2. , 1996, Neurosurgery.

[57]  M. Hayes,et al.  The effect of thalidomide on experimental tumors and metastases , 1996, Anti-cancer drugs.

[58]  R. Fahlbusch,et al.  Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. , 1996, Journal of neurosurgery.

[59]  G M Edelman,et al.  Targeted DNA recombination in vivo using an adenovirus carrying the cre recombinase gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[60]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[61]  D. Bedwell,et al.  Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations , 1996, Nature Medicine.

[62]  M. Short,et al.  Schwannomatosis , 1996, Neurology.

[63]  J. Gusella,et al.  Neurofibromatosis 2: loss of merlin's protective spell. , 1996, Current opinion in genetics & development.

[64]  X. Breakefield,et al.  Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells , 1996, Journal of virology.

[65]  R. Weissleder,et al.  Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. , 1995, Human gene therapy.

[66]  S. Jhanwar,et al.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[67]  S. Pulst,et al.  Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity and variety. , 1995, AJR. American journal of roentgenology.

[68]  M Aguet,et al.  Inducible gene targeting in mice , 1995, Science.

[69]  D. E. Weinstein,et al.  Premature Schwann Cell Differentiation and Hypermyelination in Mice Expressing a Targeted Antagonist of the POU Transcription Factor SCIP , 1995, Molecular and Cellular Neuroscience.

[70]  J. Minna,et al.  Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. , 1995, Cancer research.

[71]  T. H. van der Kwast,et al.  The product of the NF2 tumour suppressor gene localizes near the plasma membrane and is highly expressed in muscle cells. , 1995, Oncogene.

[72]  M I Kaiser-Kupfer,et al.  Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. , 1994, American journal of medical genetics.

[73]  M. Gossen,et al.  Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[74]  S. Pulst,et al.  Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. , 1994, Human molecular genetics.

[75]  L. Wrabetz,et al.  Hypomyelinating peripheral neuropathies and schwannomas in transgenic mice expressing SV40 T-antigen , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[76]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[77]  S. Pulst,et al.  Familial meningioma is not allelic to neurofibromatosis 2 , 1993, Neurology.

[78]  S. Pulst,et al.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 , 1993, Nature.

[79]  J. Haines,et al.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor , 1993, Cell.

[80]  D. Evans,et al.  A clinical study of type 2 neurofibromatosis. , 1992, The Quarterly journal of medicine.

[81]  J. Haines,et al.  Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22 , 1987, Nature.

[82]  R. Martuza,et al.  Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma , 1986, Nature.

[83]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[84]  S. Shack,et al.  Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. , 1997, Advances in experimental medicine and biology.

[85]  J. Roth,et al.  Antisense regulation of oncogenes in human cancer. , 1996, Critical reviews in oncogenesis.

[86]  D. Lenartz,et al.  Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. , 1995, The American journal of pathology.

[87]  R. Eldridge.  Central neurofibromatosis with bilateral acoustic neuroma. , 1981, Advances in neurology.